Click on the paperclip at the top of the page to add, remove or edit files. If possible, please add a row to the table below to allow easy access to your slides.
Meeting date | Uploaded by | Slides | Comments |
|---|---|---|---|
2 May 2012 | Julie | PFIM Interface 3.1 - cours M2R 10-11.pdf | |
15 May 2012 | Angelina | ||
6 June 2012 | Joe | ||
13 June 2012 | Joanna | EMA geriatric workshop - March 2012 - Shepard (submitted 19March).ppt | Terry Shepard's Slides |
12 October 2012 | Rollo | ||
9 November 2012 | Joanna | ||
13 November 2012 | Julie | ||
14 December 2012 | Lilia | Modelling neutrophil dynamics in children following bone marrow transplant | |
22 Februrary 2013 | Allienor Berges | ||
1 March 2013 | Rollo | ||
28 May 2013 | Charlotte |
9 May 2012 | PUW1 | Joanna | Immunology |
16 May 2012 | WCJ | Angelina | Zidovudine PK/PG |
23 May 2012 | PUW2 | Jig | LMWH in pregnancy |
30 May 2012 | No meeting | ||
6 June 2012 | PUW1 | Joe | Antimicrobial PKPD |
13 June 2012 | PUW1 | Terry Shepard | Geriatric PKPD |
20 June 2012 | PUW2 | Rollo/Joanna | Immunology modelling |
27 June 2012 | No meeting | ||
4th July 2012 | No meeting | ||
11th July 2012 | PUW2 | Julie | PAGE review |
18th July 2012 | PUW2 | Katie | Gentamicin in burns |
12/10/12 1pm | WCA | Rollo | Modelling of the immune reconstitution post BMT |
19/10/12 1pm | PUW3 | Joe | Prague Biometrics 2012;68:902-11 |
26/10/12 1pm | PUW3 | Charlotte | NAPPA (Beta lactam pharmacokinetics/pharmacodynamics) plans |
2/11/12 1pm | PUW3 | Eva | Neogent (developing Bayesian therapeutic drug monitoring) progress |
9/11/12 1pm | PUW3 | Joanna | Inference methods course review |
16/11/12 1pm | PUW2 | General discussion | |
23/11/12 1pm | PUW3 | Julie | Covariate selection methods in pharmacokinetic modelling |
30/11/12 1pm | PUW3 | Julie | NCA versus modelling in phase I studies for drugs with long half-life |
7/12/12 1pm | PUW3 | Goldacre talk | |
14/12/12 1pm | PUW3 | Lilia | Neutropenia post-BMT |
4/1/13 1pm | PUW3 | General discussion | |
11/1/13 1pm | Levinsky | Joe | Maraviroc PK |
18/1/13 1pm | PUW4 | Andrezj | PKPD bridging of response between adults and children |
25/1/13 1pm | PUW3 | Lilia | Neutropenia following paediatric BMT |
1/2/13 1pm | PUW1 | Mirjam Trame | Use of PKPD modeling to guide HIV understanding and treatment |
8/2/13 1pm | PUW3 | Sami | Bioequivalence studies and genetic variability |
15/2/13 1pm | PUW1 | Liana | ErbB inhibition for PKD |
22/2/13 1pm | PUW3 | Alienor Berges (GSK) | |
1/3/13 1pm | PUW4 | Rollo | CD4 reconstitution post BMT |
8/3/13 1pm | PUW3 | Eva | Neogent update |
15/3/13 1pm | PUW4 | Tafi | Dose individualisation in HIV/AIDS and TB patients on Efavirenz (EFV). |
22/3/13 1pm | PUW3 | Hui Ma | Genetic components to glucose-insulin response |
26/4/13 1pm | PUW3 | Sarit | FA and bioavailability |
10/5/13 1pm | PUW3 | Tafi | Common adverse drug reactions linked to HIV and/or TB medication: Lipodystrophy, Skin Hypersensitivity, CNS and Peripheral Neuropathy. |
28/5/13 1pm | PUW1 | Charlotte | Use of meta-analysis in evidence synthesis: an example based on dose selection for antibiotics (PAGE talk) |
31/5/13 1pm | PUW1 | Rollo | Modelling immune reconstitution in children post HSCT (PAGE talk) |
7/6/13 1pm | PUW3 | Julie | Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy (PAGE talk) |
21/6/13 1pm | PUW1 | Bruce Green | Therapeutic Drug Monitoring |
16/9/13 1pm | PUW3 | Joe | Diagnostics for bivariate regression models |
23/9/13 1pm | PUW3 | No meeting | Julie Seminar on Tues 24/9. |
30/9/13 1pm | PUW2 | Jan-Stefan Van der Walt | Nonlinear mixed effects model for saliva cortisol and cortisone in patients with Addisons disease and healthy volunteers. |
1/10/13 1pm EXTRA MEETING | PUW4 | Stefanie Hennig | Changes in between subject variability with covariate models in pharmacometrics |
7/10/13 1pm | PUW2 | ||
14/10/13 1pm | PUW3 | Tafi | TBA |
21/10/13 1pm | PUW2 | Julie | Modelling of tenofovir and emtricitabine PK in the ANRS 134-COPHAR 3 trial (work in progress) |
28/10/13 1pm | PUW3 | Joanna | CD4 recovery in the CHER study |
4/11/13 1pm | PUW2 | Eva | Upgrade talk practice |
11/11/13 1pm | PUW3 | Flora Musuamba | Use of modelling and simulation tools to improve decision-making in drug development and clinical practice |
18/11/13 1pm | PUW2 | Joe | Decision theory and antimicrobials |
25/11/13 1pm | PUW3 | Andreas | Pain PKPD |
2/12/13 1pm | TWC F | No meeting | |
9/12/13 1pm | PUW3 | Pieter de Cock | Paediatric antimicrobial PKPD in ICU |
16/12/13 1pm | PUW3 | Rollo | Modelling TCR repertoire (not with NLME!) |
20/1/14 | PUW3 | Jessica Soto | Modelling taste studies |
27/1/14 | PUW1 | Joanna | Practice for South Africa |
3/2/14 | PUW3 | Liana | PK of tyrosine kinase inhibitors in PKD animal model |
10/2/14 | PUW4 | Eva | Neogent predictions |
17/2/14 | PUW3 | Deji | Hepatitis and HIV co-infection modelling |
24/2/14 | PUW1 | ||
3/3/14 | PUW2 | Rollo | Upgrade practice |
10/3/14 | PUW1 | Joe | Clonidine PKPD for sedation in PICU |
17/3/14 | PUW3 | Andreas | Clinical protocol development for GAbapentine in Paediatric pain Project : Optimization of the trial design characteristics based on (E)D optimality using popED. |
24/3/14 | PUW3 | Julie | MRC Biostats talk on new methods for genetic covariates in PKPD modelling. |
31/3/14 | PUW1 | Flora | Clinical protocol development for GAbapentine in Paediatric Pain Project : Dose rationale and dosing schedule for characterisation efficacy in chronic pain |
7/4/14 | PUW3 | Morris | Development and dose rationale for fixed dose combinations for the treatment of tuberculosis |
14/4/14 | WCD | Andrezj | Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality |
26/4/14 | PUW4 | ||
12/5/14 | PUW2 | Carlos Hoyo | Nifedipine PKPD |
19/5/14 | WCC | Gavin Jarvis | A Modelling Approach to the Genetics of Embryonic Growth |
23/6/14 | PUW3 | All | PAGE meeting review |
30/6/14 | PUW2 | Flora | NLME cluster demonstration |
7/7/14 | PUW1 | Sophie Rhodes | The immune response to BCG vaccination over time and the population variation of immune response dynamics |
14/7/14 | PUW2 | Joanna and Jamie | An ODE model of peptide presentation by MHC-I / Geometric MCMC |
SUMMER |
1/9/14 | LGSR | Joe | Antimicrobial PKPD IDM_clinpharm_Standing_2014.pdf |
8/9/14 meeting starts 2pm | Levinski | Julie | DDMore language |
15/9/14 | LGSR | Paul | Pharmacogenetics of diclofenac |
22/9/14 | LGSR | Yucheng | Count data models and introduction to Pirana |
29/9/14 | LGSR | Andreas | Gabapentin PKPD in paediatric neuropathic pain |
6/10/14 | LGSR | Liana | Tyrosine kinase inhibitor effects in polycystic kindney disease |
13/10/14 | LGSR | Joanna | |
20/10/14 | LGSR | Rollo | Short-term neutrophil and lymphocyte HSCT models |
27/10/14 | LGSR | Eva | NeoGent PKUK practice |
3/11/14 | LGSR | Seb | Item Response Theory: Application to NLME |
10/11/14 | LGSR | Joe | A new mechanistic model for antiretroviral pharmacodynamics |
17/11/14 | LGSR | Alberto | Anaesthesia depth with 3 different EEG measures |
24/11/14 | LGSR | Suzanne Reeves | Mechanisms underpinning antipsychotic sensitivity in Alzheimer's disease |
1/12/14 | LGSR | Deji | Mixed Effect Modelling in Hep C-HIV coinfected children |
8/12/14 meeting starts at 2pm | LGSR | TBC | To be confirmed |
15/12/14 | LGSR | Morris | Understanding the determinants of drug exposure and pharmacokinetic variability in tuberculosis patients |
Date | Location* | Presenter | Topic |
|---|---|---|---|
| 12/1/15 | PUW3 | Lynette Phee | Modelling antimicrobial synergy |
| 19/1/15 | PUW3 | Michael Betancourt | Bayesian approaches in NLMEM |
| 26/1/15 | PUW4 | Deji | pre-Upgrade Talk |
| 2/2/15 | PUW3 | Joe | Study design peer review/journal club |
| 9/2/15 | PUW3 | Eva | Comparing methods for paediatric PK scaling |
| 16/2/15 | PUW3 | Ajay Sinha | Amikacin and Vancomycin PK in neonates |
| 23/2/15 | PUW4 | Julie | Joint modeling of Tenofovir plasmatic and intracellular concentrations - The COPHAR3 trial |
| 2/3/15 | PUW3 | Karin Seifert | Establishing PK/PD relationships of anti-leishmanial drugs |
| 9/3/15 | PUW3 | Joe | Antimicrobial PKPD, refresher and future directions |
| 16/3/15 | PUW3 | Sophie | Vaccine dyamics with NLME |
| 23/3/15 | PUW4 | Suzanne | Amisulpride PKPD |
| 30/3/15 | PUW3 | Morris | Determinants of variability in drug exposure and implications for dose selection in tuberculosis patients |
| 13/4/15 | PUW2 | Andreas | Gabapentin for neuropathic pain |
| 20/4/15 | PUW3 | Joe | NLME tutorial |
| 27/4/15 | PUW4 | Yucheng | Propofol in ICU |
| 11/5/15 | PUW3 | Iblal | Benzylpenicillin neonatal PK |
| 18/5/15 | PUW3 | Joe | PK of combination therapy in resistant Gm -ves |
| 1/6/15 | PUW3 | ||
| 8/6/15 | PUW3 | Liana | PKPD of in vivo PKD model |
| 15/6/15 | PUW3 | All | PAGE review |
| 22/6/15 | PUW3 | Eva | PD neonatal infection modelling |
| 29/6/15 | PUW4 | Suzanne | PKPD of amisulpride |
| 6/7/15 | PUW3 | Ludo | PKPD in veterinary medicine |
| 13/7/15 | PUW3 | Roger Gunn | PK-PD modelling of CNS PET Molecular Imaging Studies |
| 7/9/15 | PUW3 | Aiwei | Dexmeditomidine PKPD |
| 14/9/15 | PUW3 | Eva | Meropenem in late onset sepsis and meningitis in neonates |
| 21/9/15 | PUW3 | Ludo | Dexmeditomidine PKPD (in veterinary subjects) |
| 28/9/15 | PUW3 | Ben | Modelling HCMV |
| 5/10/15 | PUW1 | Suzanne | Amisulpride PK update |
| 12/10/15 | PUW1 | David Moore | PKPD in TB |
| 19/10/15 | PUW1 | Joe | Personalised medicine with PKPD |
| 26/10/15 | PUW1 | Imperial Group | Antimicrobial decision support |
| 2/11/15 | PUW1 | ||
| 9/11/15 | PUW2 | Rollo | PhD viva prep talk |
| 16/11/15 | PUW2 | Eva | IRT for neonatal sepsis |
| 23/11/15 | PUW2 | Frank | PKPD in malaria |
| 30/11/15 | PUW2 | Morris | PBPK Modelling in TB |
| 7/12/15 | PUW2 | Liana | PKD PKPD |
| 14/12/15 | PUW2 | Pratima Chowdary | Individualised dosing in haemophilia |
Date
Location* | Presenter | Topic | |
|---|---|---|---|
| 1/2/16 | PUW3 | Deji | HIV models in children |
| 4/4/16 | PUW2 | Morris | Model-based translational research in tuberculosis |
4/7/16 | PUW2 | Albert | SiRNA PD in neuroblastoma |
| 6/2/16 | PUW1 | Charlotte | Update on NAPPA |
6/6/16 | PUW2 | No meeting | PAGE |
| 7/3/16 | PUW3 | Frank | In vitro TB PD |
9/5/16 | PUW3 | Joy Dawes | Morphine and dexmeditomidine PK in children |
| 11/4/16 | PUW3 | Oliver Stirrup | Adult NLME in HIV under HAART |
11/7/16 | PUW2 | No Meeting | To be rescheduled: Min - NAPPA amoxicillin/co-amoxiclav PK results |
13/6/16 | PUW2 | Georgie | Flucloxacillin PK: Neonatal results from NAPPA |
| 14/3/16 | PUW3 | Julie | Bayesian inference in high-throughput pharmacogenetics |
| 15/2/16 | PUW3 | Yucheng | Count data modelling of BATA |
16/5/16 | PUW3 | Julie | Joint modelling of plasmatic and intracellular concentrations of Tenofovir (TDF) and Emtricitabine (FTC) - The COPHAR3 trial |
| 18/1/16 | PUW3 | Planning meeting | |
| 18/4/16 | PUW3 | Ben | Incorporating immunity into CMV models |
20/6/16 | PUW2 | Dan Wright | Model-based dose prediction: the curious case of allopurinol |
| 21/3/16 | PUW2 | Deji | Modelling poor immune response in HIV-infected children |
| 22/2/16 | PUW3 | Ben | CMV model update |
23/5/16 | PUW2 | Letizia | PBPK in TB |
| 25/1/16 | Levinski room | Joe | Scaling in PK and PD |
| 25/4/16 | PUW3 | Per Olsson | Life as a pharmacometrics consultant |
27/6/16 | PUW2 | Salvo | Neonatal antimicrobial PK |
| 29/2/16 | PUW2 | Fabrizia | PKPD in neurology |
Date
Location* | Presenter | Topic | |
|---|---|---|---|
| 12/9/16 | PUW4 | Joanna Lewis | CHER, chlamydia and reproducibility: a view from Imperial |
| 19/9/16 | PUW4 | All | R-script repository |
| 26/9/16 | PUW4 | Ben | CMV PKPD update |
| 3/10/16 | PUW1 | Lucy Hutcinson | Preclinical PD modelling in oncology |
| 10/10/16 | PUW1 | Matt Jay | Bayesian analysis of morphine safety in children |
| 17/10/16 | PUW1 | Huixin Yu | PK/PD modelling & simulation for anticancer drugs with complex absorption characteristics |
| 24/10/16 | PUW1 | Morris | Modelling combination therapy in tuberculosis |
| 31/10/16 | PUW1 | Dagan Lonsdale | Update on ABDose |
| 7/11/16 | Levinsky | Aiwei Li | Dexmeditomidine PKPD |
| 14/11/16 | Levinsky | Amy Cheung/James Yates | QSP in paediatrics/Of mice and more |
| 21/11/16 | Levinsky | Grace | Neonatal and paediatric antimicrobials |
| 28/11/16 | Levinsky | ||
| 5/12/16 | Levinsky | ||
| 12/12/16 | PUW1 | Chris W | PBPK modelling of dexamethasone + selumetinib in combination in adults and children |
| 19/12/16 | PUW1 | Charlotte | Update on NAPPA |
Date | Location* | Presenter | Topic |
|---|---|---|---|
| 19/12/16 (12:00) | PUW1 | Charlotte | Update on NAPPA |
| 16/1/17 | PUW4 | Frank | Practice MRC interview |
| 23/1/17 | PUW4 | Joe | FLACSAM PK results |
| 30/1/17 | PUW4 | All | Paediatric sample size discussion |
| 6/2/17 | PUW4 | Frank | Update on treosulfan/TB work |
| 13/2/17 | PUW4 | Mike and Sophida | MRes project outline |
| 20/2/17 | PUW2 | Ben | CMV PD |
| 27/2/17 | PUW2 | Charlotte | NAPPA update |
| 6/3/17 | PUW2 | Morris | Rationale for dose selection in tuberculosis: how to scale from mouse to human? |
| 13/3/17 | PUW2 | Benjamin Blaise | iSleep/iCare - real-time metabolic support for personalized intensive care |
| 20/3/17 | PUW2 | ||
| 27/3/17 | PUW2 | Aubrey Cunningham | Adjunctive therapy for severe malaria |
| 3/4/17 | PUW2 | Belen | PhD update |
| 10/4/17 | PUW2 | ||
| 24/4/17 | PUW1 | Annegret Dahlmann-noor | PKPD in ophthalmology |
| 8/5/17 | PUW1 | Paul Baverel | Tralokinumab, an investigational anti-IL13 monoclonal antibody: PK & exposure-response modeling to bridge adult and paediatrics clinical development plan |
| 15/5/17 | PUW1 | Morris | TB modelling PAGE practice |
| 22/5/17 | PUW1 | Ben | CMV modelling ESPID practice |
| 5/6/17 | PUW1 | No meeting | |
| 12/6/17 (12:00) | PUW3 | All | PAGE review |
| 19/6/17 | PUW1 | Ludo | HFIM progress |
| 26/6/17 | PUW1 | Maria Scarpa | End-user acceptability of orodispersible films (ODF) for delivery of medicine |
| 3/7/17 | PUW1 | ||
| 10/7/17 | PUW1 | ||
| 17/7/17 | PUW1 |
| 30/10/17 | Levinsky | ||
| 27/11/17 | Levinsky | Waty | Covariate analysis with supervised machine learning |
| 25/9/17 | PUW2 | Yomna | Treosulfan PK |
| 23/10/17 | Levinsky | ||
| 20/11/17 | Levinsky | Nicolas Fanget | Publishing in Nature journals |
| 18/12/17 | Levinsky | Ludo | HFIM modelling progress |
| 18/9/17 | Levinsky | Sophida | Posaconazole pharmacokinetics in children |
| 16/10/17 | Levinsky | Mandy W | Vitamin D PKPD plans |
| 13/11/17 | Levinsky | Shan Pan | Application of pharmacometrics in rheumatoid arthritis: case studies in clinical practice and drug development |
| 11/12/17 | Levinsky | Vicky | Rivaroxaban PKPD |
| 11/9/17 | Levinsky | no meeting | |
| 9/10/17 | Levinsky | ||
| 6/11/17 | Levinsky | Julie | PK of serum and intra cellular sustained-release Lithium |
| 4/12/17 | Levinsky | Julie | PK of total, unbound and intra cellular MPA |
| 2/10/17 | Levinsky | Ofran | Gender differences in infant mortality in UK PICUs |